|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE,
Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis
LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K,
Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR,
Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl
C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby
SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin
J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC,
Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano
T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good
PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa
A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel
SB, Lander ES, Gibbs RA, Meyerson M and Wilson RK: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y,
Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL,
Watkins CL, Armour AA and Fukuoka M: Gefitinib or
carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med.
361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T,
Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S,
Shimizu E, Saito H, Toyooka S, Nakagawa K and Fukuoka M; West Japan
Oncology Group: Gefitinib versus cisplatin plus docetaxel in
patients with non-small-cell lung cancer harbouring mutations of
the epidermal growth factor receptor (WJTOG3405): An open label,
randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010.
View Article : Google Scholar
|
|
6.
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C,
Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L
and You C: Erlotinib versus chemotherapy as first-line treatment
for patients with advanced egfr mutation-positive non-small-cell
lung cancer (optimal, CTONG-0802): A multi-centre, open-label,
randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Ou SH: Crizotinib: A novel and
first-in-class multitargeted tyrosine kinase inhibitor for the
treatment of anaplastic lymphoma kinase rearranged non-small cell
lung cancer and beyond. Drug Des Devel Ther. 5:471–485.
2011.PubMed/NCBI
|
|
8.
|
Talapatra S and Thompson CB: Growth factor
signaling in cell survival: Implications for cancer treatment. J
Pharmacol Exp Ther. 298:873–878. 2001.PubMed/NCBI
|
|
9.
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Choi Y, Zhang J, Murga C, Yu H, Koller E,
Monia BP, Gutkind JS and Li W: PTEN, but not SHIP and SHIP2,
suppresses the PI3K/Akt pathway and induces growth inhibition and
apoptosis of myeloma cells. Oncogene. 21:5289–5300. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Franke TF, Hornik CP, Segev L, Shostak GA
and Sugimoto C: PI3K/Akt and apoptosis: Size matters. Oncogene.
22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lee SH, Kim HS, Park WS, Kim SY, Lee KY,
Kim SH, Lee JY and Yoo NJ: Non-small cell lung cancers frequently
express phosphorylated Akt; an immunohistochemical study. APMIS.
110:587–592. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
14.
|
Yamaoka T, Hanada M, Ichii S, Morisada S,
Noguchi T and Yanagi Y: Cytotoxicity of amrubicin, a novel
9-aminoanthracycline, and its active metabolite amrubicinol on
human tumor cells. Jpn J Cancer Res. 89:1067–1073. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Ding Q and Zhan J: Amrubicin: Potential in
combination with cisplatin or carboplatin to treat small-cell lung
cancer. Drug Des Devel Ther. 7:681–689. 2013.PubMed/NCBI
|
|
16.
|
Sawa T, Yana T, Takada M, Sugiura T, Kudoh
S, Kamei T, Isobe T, Yamamoto H, Yokota S, Katakami N, Tohda Y,
Kawakami A, Nakanishi Y and Ariyoshi Y: Multicenter phase II study
of amrubicin, 9-amino-anthracycline, in patients with advanced
non-small-cell lung cancer (study 1): West Japan Thoracic Oncology
Group (WJTOG) trial. Invest New Drugs. 24:151–158. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ueda Y, Igishi T, Hashimoto K, Suyama H,
Araki K, Sumikawa T, Takeda K, Nakazaki H, Matsunami K, Kodani M,
Shigeoka Y, Matsumoto S and Shimizu E: Synergistic cell growth
inhibition by the combination of amrubicin and Akt-suppressing
tyrosine kinase inhibitors in small cell lung cancer cells:
Implication of c-Src and its inhibitor. Int J Oncol. 34:689–696.
2009.PubMed/NCBI
|
|
18.
|
Takata M, Chikumi H, Miyake N, Adachi K,
Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E and Shimizu E:
Lack of Akt activation in lung cancer cells with egfr mutation is a
novel marker of cetuximab sensitivity. Cancer Biol Ther.
13:369–378. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Steel GG and Peckham MJ: Exploitable
mechanisms in combined radiotherapy-chemotherapy: The concept of
additivity. Int J Radiat Oncol Biol Phys. 5:85–91. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Ono M and Kuwano M: Molecular mechanisms
of epidermal growth factor receptor (EGFR) activation and response
to gefitinib and other EGFR-targeting drugs. Clin Cancer Res.
12:7242–7251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Oh SJ, Erb HH, Hobisch A, Santer FR and
Culig Z: Sorafenib decreases proliferation and induces apoptosis of
prostate cancer cells by inhibition of the androgen receptor and
Akt signaling pathways. Endocr Relat Cancer. 19:305–319. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ma PC, Tretiakova MS, Nallasura V,
Jagadeeswaran R, Husain AN and Salgia R: Downstream signalling and
specific inhibition of c-met/HGF pathway in small cell lung cancer:
Implications for tumour invasion. Br J Cancer. 97:368–377. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Khwaja A, Rodriguez-Viciana P, Wennstrom
S, Warne PH and Downward J: Matrix adhesion and Ras transformation
both activate a phosphoinositide 3-OH kinase and protein kinase
B/Akt cellular survival pathway. EMBO J. 16:2783–2793. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and
Haber DA: Activating mutations in the epidermal growth factor
receptor underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Fukuoka M, Yano S, Giaccone G, Tamura T,
Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S,
Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S,
Macleod A, Feyereislova A, Dong RP and Baselga J:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003.
|
|
27.
|
Nakagawa K, Tamura T, Negoro S, Kudoh S,
Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose
M, Dong RP and Fukuoka M: Phase I pharmacokinetic trial of the
selective oral epidermal growth factor receptor tyrosine kinase
inhibitor gefitinib (‘Iressa’, ZD1839) in japanese patients with
solid malignant tumors. Ann Oncol. 14:922–930. 2003.
|
|
28.
|
Hidalgo M, Siu LL, Nemunaitis J, Rizzo J,
Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis
L, Ferrante K, Von Hoff DD, Silberman S and Rowinsky EK: Phase I
and pharmacologic study of OSI-774, an epidermal growth factor
receptor tyrosine kinase inhibitor, in patients with advanced solid
malignancies. J Clin Oncol. 19:3267–3279. 2001.
|
|
29.
|
Fujiwara Y, Kawada K, Takano D, Tanimura
S, Ozaki K and Kohno M: Inhibition of the PI3 kinase/Akt pathway
enhances doxorubicin-induced apoptotic cell death in tumor cells in
a p53-dependent manner. Biochem Biophys Res Commun. 340:560–566.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Navas C, Hernandez-Porras I, Schuhmacher
AJ, Sibilia M, Guerra C and Barbacid M: EGF receptor signaling is
essential for K-ras oncogene-driven pancreatic ductal
adenocarcinoma. Cancer Cell. 22:318–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Minjgee M, Toulany M, Kehlbach R, Giehl K
and Rodemann HP: K-RAS(V12) induces autocrine production of EGFR
ligands and mediates radioresistance through EGFR-dependent Akt
signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys.
81:1506–1514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Farin K, Schokoroy S, Haklai R, Cohen-Or
I, Elad-Sfadia G, Reyes-Reyes ME, Bates PJ, Cox AD, Kloog Y and
Pinkas-Kramarski R: Oncogenic synergism between erbb1, nucleolin,
and mutant ras. Cancer Res. 71:2140–2151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Tal-Or P, Erlich S, Porat-Shliom N,
Goldshmit Y, Ben-Baruch G, Shaharabani E, Kloog Y and
Pinkas-Kramarski R: Ligand-independent regulation of ErBb4 receptor
phosphorylation by activated ras. J Cell Biochem. 98:1482–1494.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Carrasco-Garcia E, Saceda M, Grasso S,
Rocamora-Reverte L, Conde M, Gomez-Martinez A, Garcia-Morales P,
Ferragut JA and Martinez-Lacaci I: Small tyrosine kinase inhibitors
interrupt EGFR signaling by interacting with erbB3 and erbB4 in
glioblastoma cell lines. Exp Cell Res. 317:1476–1489. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Eberhard DA, Johnson BE, Amler LC, Goddard
AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson
DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D,
Stinson JA, Zhang YR, Seshagiri S and Hillan KJ: Mutations in the
epidermal growth factor receptor and in KRAS are predictive and
prognostic indicators in patients with non-small-cell lung cancer
treated with chemotherapy alone and in combination with erlotinib.
J Clin Oncol. 23:5900–5909. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Ohe Y, Negoro S, Matsui K, Nakagawa K,
Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N,
Fukuoka M and Ariyoshi Y: Phase I–II study of amrubicin and
cisplatin in previously untreated patients with extensive-stage
small-cell lung cancer. Ann Oncol. 16:430–436. 2005.
|
